Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMID 22806594)

Published in Clin Infect Dis on July 17, 2012

Authors

Michael Uhlin1, Jens Gertow, Mehmet Uzunel, Mantas Okas, Sofia Berglund, Emma Watz, Mats Brune, Per Ljungman, Mark Maeurer, Jonas Mattsson

Author Affiliations

1: Therapeutic Immunology Unit, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Michael.uhlin@ki.se

Articles citing this

Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev (2014) 1.43

Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. Immunol Cell Biol (2017) 1.09

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica (2013) 0.95

Antiviral T-cell therapy. Immunol Rev (2014) 0.91

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol (2014) 0.91

Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One (2013) 0.86

Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. Biol Blood Marrow Transplant (2015) 0.85

Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. Bone Marrow Transplant (2016) 0.82

Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81

CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence (2016) 0.81

Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology (2014) 0.81

Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation. PLoS One (2014) 0.79

CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers. J Transl Med (2014) 0.79

Antiviral cell therapy: is this the future? Blood (2013) 0.77

T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood (2016) 0.77

Immunotherapy: opportunities, risks and future perspectives. Cytotherapy (2014) 0.77

Preventing stem cell transplantation-associated viral infections using T-cell therapy. Immunotherapy (2015) 0.77

Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood. J Transl Med (2015) 0.76

Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. Front Immunol (2017) 0.75

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood. Mol Ther Methods Clin Dev (2017) 0.75

Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. Front Immunol (2016) 0.75

Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation. Immunotargets Ther (2014) 0.75

Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7. Front Immunol (2015) 0.75

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia (2017) 0.75

Articles by these authors

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77

Concern Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. Lancet (2011) 5.79

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33

How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19

Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09

NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91

Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica (2005) 1.90

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90

2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81

A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation (2004) 1.75

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood (2002) 1.71

2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2011) 1.68

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica (2010) 1.68

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2011) 1.54

Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50

Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation (2004) 1.43

Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. Pediatr Transplant (2014) 1.43

The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood. Pediatr Transplant (2011) 1.42

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation (2010) 1.42

Biliary epithelial cell antibodies induce expression of toll-like receptors 2 and 3: a mechanism for post-liver transplantation cholangitis? Liver Transpl (2005) 1.40

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood (2013) 1.27

Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Circulation (2004) 1.26

Autologous stem cell transplantation for systemic lupus erythematosus. Lupus (2004) 1.24

Retracted Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood (2005) 1.23

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood (2008) 1.23

Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol (2003) 1.21

Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation (2009) 1.20

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis (2012) 1.20

Maternal microchimerism in human fetal tissues. Am J Obstet Gynecol (2008) 1.20

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18

Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood (2006) 1.17

The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica (2006) 1.15

Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant (2009) 1.15

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood (2002) 1.14

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14

Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol (2002) 1.13

Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol (2009) 1.10

A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods (2003) 1.09

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood (2006) 1.09

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant (2011) 1.09

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine (2010) 1.06

Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB. J Infect (2008) 1.06

A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS (2008) 1.05

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis (2013) 1.03

Streptococcus viridans septicaemia: a comparison study in patients admitted to the departments of infectious diseases and haematology in a university hospital. Scand J Infect Dis (2002) 1.03

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol (2006) 1.03

The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother (2009) 1.02

Viral infections in immunocompromised patients. Biol Blood Marrow Transplant (2011) 1.01

Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis (2009) 1.01

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. Cancer (2011) 0.99

Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica (2014) 0.99

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood (2002) 0.99

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J (2012) 0.99

Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells (2013) 0.98

Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation (2008) 0.97

Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.96

Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 0.96

Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. Biol Blood Marrow Transplant (2013) 0.96

HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother (2009) 0.96

Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2004) 0.96

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica (2013) 0.95

NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. Br J Haematol (2006) 0.95

Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation (2006) 0.95

Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant (2010) 0.94

Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Transplantation (2006) 0.94

QuantiFERON-TB GOLD ELISA assay for the detection of Mycobacterium tuberculosis-specific antigens in blood specimens of HIV-positive patients in a high-burden country. FEMS Immunol Med Microbiol (2009) 0.93

Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood (2007) 0.92

Adult porcine islets produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation (2004) 0.91

Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation. Cancer Nurs (2004) 0.90

Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.90

A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant (2013) 0.90

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol (2009) 0.89

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol (2002) 0.89